Bone Therapeutics SA

Addressing issues associated with bringing iSPC-derived MSCs to the clinic 0:44
Addressing issues associated with bringing iSPC-derived MSCs to the clinic
Tony Ting • 26 Jan 2022
Enhancing the therapeutic capacity of MSCs 1:48
Enhancing the therapeutic capacity of MSCs
Tony Ting • 26 Jan 2022
Evaluating the development of iSPC-derived MSCs 0:39
Evaluating the development of iSPC-derived MSCs
Tony Ting • 26 Jan 2022
The ISCT’s ongoing battle against unproven cell & gene therapies 2:32
The ISCT’s ongoing battle against unproven cell & gene therapies
Miguel Forte • 5 Oct 2021
Developing iPSC-derived MSCs for therapeutic purposes 1:45
Developing iPSC-derived MSCs for therapeutic purposes
Miguel Forte • 5 Oct 2021
Learnings from the COVID-19 pandemic for the advanced therapies sector 2:04
Learnings from the COVID-19 pandemic for the advanced therapies sector
Miguel Forte • 5 Oct 2021
Addressing the unproven cell-based therapy market 3:14
Addressing the unproven cell-based therapy market
Miguel Forte • 26 May 2021
Improving patient access to cell & gene therapies 3:45
Improving patient access to cell & gene therapies
Miguel Forte • 26 May 2021
Off-the-shelf cell therapy for bone indications: ALLOB & JTA-004 4:54
Off-the-shelf cell therapy for bone indications: ALLOB & JTA-004
Miguel Forte • 26 May 2021
The content of VJRegenMed is intended for healthcare professionals